53 Hepsera generics waiting for regulatory approval
Published: 2010-04-08 07:00:00
Updated: 2010-04-08 07:00:00
A total of 53 domestic drug makers are waiting for the green light of the Korea Food and Drug Administration to launch their generics for GlaxoSmithKline’s Hepsera (adefovir dipivoxil) as the re-examination period of the original brand was already expired on February 18.
Of the 53 generic prod...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
